Scarica l'app Stockscreener
2.92
3.18%
0.09
Pre-mercato:
2.91
-0.010
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.83
Aprire:
$2.88
Volume 24 ore:
281.28K
Relative Volume:
2.47
Capitalizzazione di mercato:
$27.42M
Reddito:
$2.05M
Utile/perdita netta:
$-27.28M
Rapporto P/E:
-0.1944
EPS:
-15.02
Flusso di cassa netto:
$-18.89M
1 W Prestazione:
+6.96%
1M Prestazione:
+17.74%
6M Prestazione:
+35.81%
1 anno Prestazione:
+175.97%
Intervallo 1D:
$2.73
$3.07
Intervallo di 1 settimana:
$2.66
$3.07
Portata 52W:
$1.03
$4.98
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Confronta IBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.92 | 27.42M | 2.05M | -27.28M | -18.89M | -15.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
iBio Inc Borsa (IBIO) Ultime notizie
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
I: Weekly TechBio News - substack.com
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Announces Successful Closing of Private Placement OfferingOn January 10, 2025, iBio, Inc. (NYSE American: IBIO) announced the completion of a private placement offering, marking an important development for the company. The securities purchase a - Defense World
iBio director Parada acquires $499,998 in common stock By Investing.com - Investing.com Australia
iBio director William Clark purchases $4,999 in common stock By Investing.com - Investing.com Australia
Felipe Duran Increases Stake in iBio Inc with Recent Share Purch - GuruFocus.com
Director David Arkowitz Acquires 18,382 Shares of iBio Inc (IBIO) - GuruFocus.com
Insider Buying: Gary Sender Acquires 9,191 Shares of iBio Inc (I - GuruFocus.com
Ibio's chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Australia
iBio director Gary Sender purchases $24,999 in common stock By Investing.com - Investing.com Australia
Ibio CEO Brenner Martin acquires $24,999 in stock By Investing.com - Investing.com Australia
Ibio's CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Australia
iBio director Arkowitz purchases $49,999 in common stock By Investing.com - Investing.com Australia
Ibio’s CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Nigeria
Ibio’s chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Nigeria
iBio director William Clark purchases $4,999 in common stock - Investing.com India
iBio director Arkowitz purchases $49,999 in common stock - Investing.com India
iBio Inc. stock falls Monday, underperforms market - MarketWatch
Ibio's CFO Duran Felipe buys $24,999 in common stock - Investing.com
iBio Announces New Investments from Board Members and Officers - The Manila Times
** - Defense World
iBio Advances Antibody Development for Obesity Treatment - TipRanks
Ibio licenses long-acting anti-myostatin antibody from Astralbio - BioWorld Online
iBio develops antibody for cardiometabolic disorders and obesity - Investing.com
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio - The Manila Times
iBio and AstralBio Breakthrough: Novel Antibody Targets Obesity and Diabetes Through Activin E Inhibition - StockTitan
iBio Inc. stock rises Monday, still underperforms market - MarketWatch
iBio Enters Exclusive License Agreement with AstralBio for Development of Anti-Myostatin Antibody - Defense World
SABBY MANAGEMENT, LLC Acquires 19,250 Shares of iBio Inc - GuruFocus.com
iBio Inc. stock rises Friday, still underperforms market - MarketWatch
iBio Expands Pipeline with New Antibody Agreement - Yahoo Finance
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform - AOL
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio - The Manila Times
iBio expands cardiometabolic and obesity program (NYSE:IBIO) - Seeking Alpha
iBio (NYSE:IBIO) Stock Price Up 2.5% – Should You Buy? - Defense World
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio Inc. stock falls Wednesday, still outperforms market - MarketWatch
LUCID CAPITAL MARKETS Initiates Coverage of iBio (IBIO) with Buy Recommendation - MSN
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):